Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q3 2025 (← Previous) (Next →)

Filing Date: Nov 10, 2025

Total Value ($000): $212,453 (100.0% shares, 0.0% debt)

Holdings (9)

LENZ Lenz Therapeutics, Inc. 58.3%

Value ($000) $123,758 Shares 2,656,888 Est. Cost $36.77 Unrealized 0.0%

GLUE Monte Rosa Therapeutics, Inc. 19.7%

Value ($000) $41,888 Shares 5,652,922 Est. Cost $7.50 Unrealized -29.4%

JBIO Jade Biosciences, Inc. 6.2%

Value ($000) $13,168 Shares 1,525,820 Est. Cost $33.31 Unrealized -75.5%

CRSP CRISPR Therapeutics AG 4.5%

Value ($000) $9,646 Shares 148,831 Est. Cost $40.26 Unrealized +42.6%

SKYE Skye Bioscience, Inc. 3.7%

Value ($000) $7,890 Shares 2,007,704 Est. Cost $7.75 Unrealized -51.3%

CTNM Contineum Therapeutics, Inc. 3.0%

Value ($000) $6,376 Shares 542,628 Est. Cost $16.10 Unrealized -49.9%

— Repare Therapeutics, Inc. 2.2%

Value ($000) $4,658 Shares 2,646,657 Est. Cost $10.58 Unrealized —

— Tempest Therapeutics, Inc. 1.3%

Value ($000) $2,773 Shares 269,772 Est. Cost $6.80 Unrealized —

— Adverum Biotechnologies, Inc. 1.1%

Value ($000) $2,296 Shares 506,821 Est. Cost $9646.10 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
LENZ	Lenz Therapeutics, Inc.	2,656,888	$123,758	58.3%	$36.77	0.0%	Common Stock	52635N103
GLUE	Monte Rosa Therapeutics, Inc.	5,652,922	$41,888	19.7%	$7.50	-29.4%	Common Stock	61225M102
JBIO	Jade Biosciences, Inc.	1,525,820	$13,168	6.2%	$33.31	-75.5%	Common Stock	008064206
CRSP	CRISPR Therapeutics AG	148,831	$9,646	4.5%	$40.26	+42.6%	Common Shares	H17182108
SKYE	Skye Bioscience, Inc.	2,007,704	$7,890	3.7%	$7.75	-51.3%	Common Stock	83086J200
CTNM	Contineum Therapeutics, Inc.	542,628	$6,376	3.0%	$16.10	-49.9%	Common Stock	21217B100
—	Repare Therapeutics, Inc.	2,646,657	$4,658	2.2%	$10.58	—	Common Stock	760273102
—	Tempest Therapeutics, Inc.	269,772	$2,773	1.3%	$6.80	—	Common Stock	87978U108
—	Adverum Biotechnologies, Inc.	506,821	$2,296	1.1%	$9646.10	—	Common Stock	00773U108